Baird lowered the firm’s price target on Intellia Therapeutics (NTLA) to $4 from $9 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results where it said the latest update threatens to completely derail the pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics: Hold Rating Amid Safety Concerns and Regulatory Challenges
- Intellia Therapeutics price target lowered to $12 from $17 at Wells Fargo
- Intellia Therapeutics price target lowered to $21 from $29 at Citizens JMP
- Intellia Therapeutics price target lowered to $14 from $24 at Barclays
- Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty